Anthony Auriemma
Family Medicine · Westmont, ILNPI 1578507562
Payments from drug & device makers
Across 1,224 payments — averaging $643.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$467K
- Lilly USA, LLC$146K
- Vivus LLC$98K
- Currax Pharmaceuticals LLC$30K
- Nestle Healthcare Nutrition Inc.$20K
- Bausch Health US, LLC$10K
- plus $17K from 20 others
What the payments were for
- Consulting fees$137,39117%
- Speaking & faculty fees$544,46269%
- Travel & lodging$84,81411%
- Food & beverage$21,2043%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 665 | $467,025 |
| Lilly USA, LLC | 294 | $145,579 |
| Vivus LLC | 38 | $98,063 |
| Currax Pharmaceuticals LLC | 88 | $29,898 |
| Nestle Healthcare Nutrition Inc. | 18 | $19,958 |
| Bausch Health US, LLC | 3 | $10,417 |
| Boehringer Ingelheim | 11 | $5,422 |
| Novo Nordisk AS | 4 | $5,367 |
| Eli Lilly | 3 | $4,747 |
| Kvk-tech, Inc. | 61 | $349 |
| Jazz Pharmaceuticals Inc. | 5 | $210 |
| Bayer | 8 | $205 |
| Rhythm Pharmaceuticals, Inc. | 5 | $188 |
| Corcept Therapeutics | 5 | $160 |
| Amarin Pharma, Inc. | 1 | $123 |
| Phathom Pharmaceuticals, Inc. | 1 | $122 |
| Endo Pharmaceuticals Inc. | 3 | $56 |
| Eisai Inc. | 2 | $40 |
| AbbVie | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| AstraZeneca | 1 | $26 |
| Boston Scientific | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Shield Therapeutics Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Echosens North America, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$788,090 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 199 | $255,596 |
| MounjaroTirzepatide | 177 | $224,430 |
| WegovySemaglutide | 59 | $96,021 |
| Topiramate | 83 | $906 |
| Bupropion XlBupropion Hcl | 32 | $784 |
| Metformin Hcl ErMetformin Hcl | 58 | $658 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $479 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $361 |
| Metformin Hcl | 20 | $300 |
| Levothyroxine Sodium | 16 | $232 |
| Atorvastatin Calcium | 19 | $231 |
| Losartan Potassium | 18 | $174 |
| Rosuvastatin Calcium | 16 | $123 |
| Ondansetron OdtOndansetron | 24 | $120 |
| Hydrochlorothiazide | 13 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $467,025 | $351,617258 claims |
| Lilly USA, LLCMounjaro | $145,579 | $224,430177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Westmont
- Paula BarnesWestmont$182K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.